Drug intelligence / Profile preview

UI122

Development stage: Preclinical
Lead developer: Korea United Pharm
Modality: Small Molecules

Overview

UI122 is a small molecule drug candidate being developed by Korea United Pharm for the treatment of bronchitis. It is categorized as an Incrementally Modified Drug (IMD), a classification used by the developer for reformulations, new dosage forms, or new combinations of existing medications designed to improve therapeutic outcomes. UI122 is currently in the preclinical stage of development.

Beyond the preview

Go deeper on UI122.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UI122.

Explore the full profile